author-photo

J.E. Rosenberg

Memorial Sloan Kettering Cancer Center

7

Papers

62

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

901OEV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (31)
927PClinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
921PQuality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
223TiPEV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
940PcfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (26)